The Safety and Efficacy of Lucinactant for Inhalation in Premature Neonates 26 to 32 Weeks Gestational Age

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2015
The primary objective of this study is to evaluate the safety and efficacy of lucinactant for inhalation administered as an aerosolized dose in two doses to preterm neonates 26 - 32 weeks gestational age who are receiving nasal continuous positive airway pressure (nCPAP) for Respiratory Distress Syndrome (RDS) compared to neonates receiving nCPAP alone.
Epistemonikos ID: f7ebd1c1416e9e925ebd58cc4154834fda908ccd
First added on: May 12, 2024